Mrs Pascale Augé appointed as Chief Executive Officer, Inserm Transfert
On January 1st 2006, Inserm entrusted all its technology and knowledge transfer activities to Inserm Transfert under a public service delegation agreement. Inserm Transfert’s total revenues reached €11.5m in 2013, with a 63% growth over the past three years.
Inserm Transfert, as a shareholder, has a seat on the Supervisory Board of Inserm Transfert Initiative, and will be represented by its CEO.
Inserm Transfert Initiative becomes a permanent guest on the Supervisory Board of Inserm Transfert, and will be represented by its President.
These decisions, effective April 1st 2014, consolidate the organisation of Inserm’s technology transfer activities and pre-seed and seed financing of young biotechnology start-ups